New Compounding Laws Don’t Change FDA Position on Makena

Washington Drug Letter
The FDA does not intend to prevent compounders from making preterm birth drug Makena (hydroxyprogesterone caproate), the agency stated in a legal filing earlier this month that outlines how it intends to approach one contentious issue involving compounders.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00